Transglutaminase 1 Replacement Therapy Successfully Mitigates the ARCI Phenotype in Full-Thickness Skin Disease Equivalents

Roswitha Plank, Guy Yealland, Enrico Miceli, Dulce Lima Cunha, Patrick Graff, Sari Thomforde, Robert Gruber, Verena Moosbrugger-Martinz, Katja Eckl, Marcelo Calderón, Hans Christian Hennies, Sarah Hedtrich

Research output: Contribution to journalArticle

62 Downloads (Pure)

Abstract

This is a letter to the editor
Original languageEnglish
JournalJournal of Investigative Dermatology
Early online date15 Nov 2018
DOIs
Publication statusPublished - 15 Nov 2018

Keywords

  • ARCI
  • Tgase-1
  • enzyme-replacement therapy
  • nanoparticles
  • 3D skin modelling
  • ichthyosis
  • orphan drug
  • tNG
  • TWEL

Fingerprint Dive into the research topics of 'Transglutaminase 1 Replacement Therapy Successfully Mitigates the ARCI Phenotype in Full-Thickness Skin Disease Equivalents'. Together they form a unique fingerprint.

  • Profiles

    No photo of KATJA ECKL

    Dr KATJA ECKL

    • Biology - Senior Lecturer in Biology

    Person: Academic

    Cite this

    Plank, R., Yealland, G., Miceli, E., Cunha, D. L., Graff, P., Thomforde, S., Gruber, R., Moosbrugger-Martinz, V., Eckl, K., Calderón, M., Hennies, H. C., & Hedtrich, S. (2018). Transglutaminase 1 Replacement Therapy Successfully Mitigates the ARCI Phenotype in Full-Thickness Skin Disease Equivalents. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2018.11.002